These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34045800)

  • 21. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
    Young MJ; Clyne CD; Chapman KE
    J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
    de Abajo FJ; Rodríguez-Martín S; Lerma V; Mejía-Abril G; Aguilar M; García-Luque A; Laredo L; Laosa O; Centeno-Soto GA; Ángeles Gálvez M; Puerro M; González-Rojano E; Pedraza L; de Pablo I; Abad-Santos F; Rodríguez-Mañas L; Gil M; Tobías A; Rodríguez-Miguel A; Rodríguez-Puyol D;
    Lancet; 2020 May; 395(10238):1705-1714. PubMed ID: 32416785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis.
    Ssentongo AE; Ssentongo P; Heilbrunn ES; Lekoubou A; Du P; Liao D; Oh JS; Chinchilli VM
    Open Heart; 2020 Nov; 7(2):. PubMed ID: 33154144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controversial Roles of the Renin Angiotensin System and Its Modulators During the COVID-19 Pandemic.
    Gressens SB; Leftheriotis G; Dussaule JC; Flamant M; Levy BI; Vidal-Petiot E
    Front Physiol; 2021; 12():624052. PubMed ID: 33692701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of renin-angiotensin-aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies.
    Zhang K; Cao L; Xuan N; Huang T; Tian B; Cui W; Zhang G; Zhang S
    J Intensive Med; 2022 Oct; 2(4):282-290. PubMed ID: 36785646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: a Systematic Review and Meta-analysis of 28,872 Patients.
    Baral R; White M; Vassiliou VS
    Curr Atheroscler Rep; 2020 Aug; 22(10):61. PubMed ID: 32830286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.
    Şenkal N; Meral R; Medetalibeyoğlu A; Konyaoğlu H; Kose M; Tukek T
    Anatol J Cardiol; 2020 Jul; 24(1):21-29. PubMed ID: 32628137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19).
    Banwait R; Singh D; Blanco A; Rastogi V; Abusaada K
    Cureus; 2021 Feb; 13(2):e13429. PubMed ID: 33758716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19 Severity.
    Alhaddad MJ; Almulaify MS; Alshabib AA; Alwesaibi AA; Alkhameys MA; Alsenan ZK; Alsheef HJ; Alsaghirat MA; Almomtan MS; Alshakhs MN
    Cureus; 2022 Mar; 14(3):e22903. PubMed ID: 35399441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease.
    ElAbd R; AlTarrah D; AlYouha S; Bastaki H; Almazeedi S; Al-Haddad M; Jamal M; AlSabah S
    Front Med (Lausanne); 2021; 8():600385. PubMed ID: 33748156
    [No Abstract]   [Full Text] [Related]  

  • 32. [Renin-angiotensin-aldosterone system : brief history and questions related to the COVID-19 pandemic].
    Valdes-Socin H; Jouret F; Vroonen L; Scheen AJ; Lancellotti P
    Rev Med Liege; 2020 Sup; 75(S1):123-129. PubMed ID: 33211434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 in Patients with Hypertension.
    Quinaglia T; Shabani M; Rezaei N
    Adv Exp Med Biol; 2021; 1318():243-261. PubMed ID: 33973183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019.
    Gilbert RE; Caldwell L; Misra PS; Chan K; Burns KD; Wrana JL; Yuen DA
    Can J Diabetes; 2021 Mar; 45(2):162-166.e1. PubMed ID: 32917504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ramipril in High-Risk Patients With COVID-19.
    Amat-Santos IJ; Santos-Martinez S; López-Otero D; Nombela-Franco L; Gutiérrez-Ibanes E; Del Valle R; Muñoz-García E; Jiménez-Diaz VA; Regueiro A; González-Ferreiro R; Benito T; Sanmartin-Pena XC; Catalá P; Rodríguez-Gabella T; Delgado-Arana JR; Carrasco-Moraleja M; Ibañez B; San Román JA
    J Am Coll Cardiol; 2020 Jul; 76(3):268-276. PubMed ID: 32470515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
    Melissa Hallow K; Dave I
    Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.